Larimar Therapeutics (LRMR) Competitors $1.90 +0.07 (+3.53%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$1.90 -0.01 (-0.52%) As of 04/17/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. GHRS, KURA, CRMD, SAGE, CGEM, MRVI, TYRA, SIGA, RLAY, and AKBAShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include GH Research (GHRS), Kura Oncology (KURA), CorMedix (CRMD), Sage Therapeutics (SAGE), Cullinan Therapeutics (CGEM), Maravai LifeSciences (MRVI), Tyra Biosciences (TYRA), SIGA Technologies (SIGA), Relay Therapeutics (RLAY), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. GH Research Kura Oncology CorMedix Sage Therapeutics Cullinan Therapeutics Maravai LifeSciences Tyra Biosciences SIGA Technologies Relay Therapeutics Akebia Therapeutics GH Research (NASDAQ:GHRS) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment. Is GHRS or LRMR more profitable? GH Research's return on equity of -20.29% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -20.29% -19.49% Larimar Therapeutics N/A -35.87%-32.37% Does the media prefer GHRS or LRMR? In the previous week, Larimar Therapeutics had 1 more articles in the media than GH Research. MarketBeat recorded 1 mentions for Larimar Therapeutics and 0 mentions for GH Research. Larimar Therapeutics' average media sentiment score of 1.34 beat GH Research's score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment GH Research Neutral Larimar Therapeutics Positive Which has better earnings & valuation, GHRS or LRMR? GH Research is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$35.59M-$0.75-12.13Larimar TherapeuticsN/AN/A-$36.95M-$1.30-1.47 Do insiders and institutionals have more ownership in GHRS or LRMR? 56.9% of GH Research shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 3.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer GHRS or LRMR? Larimar Therapeutics received 16 more outperform votes than GH Research when rated by MarketBeat users. However, 76.92% of users gave GH Research an outperform vote while only 71.88% of users gave Larimar Therapeutics an outperform vote. CompanyUnderperformOutperformGH ResearchOutperform Votes3076.92% Underperform Votes923.08% Larimar TherapeuticsOutperform Votes4671.88% Underperform Votes1828.13% Which has more risk & volatility, GHRS or LRMR? GH Research has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Do analysts recommend GHRS or LRMR? GH Research currently has a consensus price target of $30.86, suggesting a potential upside of 239.09%. Larimar Therapeutics has a consensus price target of $19.63, suggesting a potential upside of 930.18%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 SummaryLarimar Therapeutics beats GH Research on 10 of the 16 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$121.97M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.29%P/E Ratio-1.666.9521.9417.81Price / SalesN/A231.03380.9597.70Price / CashN/A65.6738.2634.64Price / Book1.025.936.453.98Net Income-$36.95M$143.22M$3.22B$247.81M1 Month Performance-25.88%-13.56%-9.76%-7.91%1 Year Performance-70.83%-8.89%11.49%1.53% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics3.2153 of 5 stars$1.91+3.5%$19.63+930.2%-70.1%$121.97MN/A-1.6630Positive NewsGHRSGH Research2.4118 of 5 stars$9.09+1.0%$30.86+239.5%-18.7%$472.94MN/A-11.5110Gap DownKURAKura Oncology4.1769 of 5 stars$5.85+1.4%$25.50+335.9%-66.6%$472.42M$53.88M-2.48130Positive NewsHigh Trading VolumeCRMDCorMedix2.8478 of 5 stars$7.13+3.2%$14.50+103.4%+41.5%$464.75M$43.47M-8.8030SAGESage Therapeutics3.9714 of 5 stars$7.40+3.4%$8.81+19.1%-43.0%$454.96M$41.24M-1.12690Upcoming EarningsAnalyst RevisionNews CoverageGap UpCGEMCullinan Therapeutics2.2405 of 5 stars$7.74+0.4%$32.86+324.5%-56.3%$452.89MN/A-2.7330Analyst ForecastNews CoveragePositive NewsMRVIMaravai LifeSciences4.2805 of 5 stars$1.77-3.3%$6.34+258.4%-76.7%$450.18M$259.19M-1.08610Options VolumeTYRATyra Biosciences2.3387 of 5 stars$8.43+5.9%$30.83+265.8%-39.2%$447.55MN/A-5.2420News CoveragePositive NewsSIGASIGA Technologies2.0336 of 5 stars$6.15+3.2%N/A-27.2%$439.34M$138.72M5.1340Options VolumeNews CoveragePositive NewsRLAYRelay Therapeutics2.7032 of 5 stars$2.57+6.2%$19.80+670.4%-56.0%$435.67M$10.01M-0.98330Analyst ForecastNews CoveragePositive NewsGap UpAKBAAkebia Therapeutics3.3687 of 5 stars$1.83+10.9%$6.50+255.2%+48.2%$432.30M$160.18M-7.96430Gap Up Related Companies and Tools Related Companies GH Research Alternatives Kura Oncology Alternatives CorMedix Alternatives Sage Therapeutics Alternatives Cullinan Therapeutics Alternatives Maravai LifeSciences Alternatives Tyra Biosciences Alternatives SIGA Technologies Alternatives Relay Therapeutics Alternatives Akebia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
